GH Research (GHRS) Accounts Payables (2021 - 2026)
GH Research (GHRS) posted quarterly Accounts Payables of $3.8 million for Q4 2025, up 0.86% year-over-year from $3.7 million in Q4 2024, and down 1.67% quarter-over-quarter from $3.8 million in Q3 2025.
GH Research (GHRS) Accounts Payables (2021 - 2026) Analysis & Trends
GH Research's Accounts Payables history runs 5 years deep, the most recent figure standing at $3.8 million for Q4 2025.
- In Q4 2025, Accounts Payables rose 0.86% year-over-year to $3.8 million; the TTM figure through Dec 2025 stood at $3.8 million (up 0.86% YoY), while the FY2025 annual figure was $3.8 million, up 0.86% from the prior year.
- Accounts Payables for Q4 2025 stood at $3.8 million, down from $3.8 million in the prior quarter.
- The five-year high for Accounts Payables was $4.8 million in Q1 2025, with the low at $399000.0 in Q4 2021.
- The 5-year median for Accounts Payables is $2.9 million (2023), against an average of $2.7 million.
- The sharpest annual moves came in 2022 and 2024: Accounts Payables surged 368.17% in 2022, then retreated 11.68% in 2024.
- GH Research's Accounts Payables stood at $399000.0 in 2021, then soared by 368.17% to $1.9 million in 2022, then soared by 86.83% to $3.5 million in 2023, then grew by 7.19% to $3.7 million in 2024, then gained by 0.86% to $3.8 million in 2025.
- Business Quant data shows GHRS's Accounts Payables at $3.8 million in Q4 2025, $3.8 million in Q3 2025, and $3.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | GH Research | 2.02 Bn | 1.68 Bn | - | 5.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.93 Mn |
| Dec 31, 2025 | 3.77 Mn |
| Sep 30, 2025 | 3.84 Mn |
| Jun 30, 2025 | 3.45 Mn |
| Mar 31, 2025 | 4.77 Mn |
| Dec 31, 2024 | 3.74 Mn |
| Sep 30, 2024 | 2.95 Mn |
| Jun 30, 2024 | 2.57 Mn |
| Mar 31, 2024 | 3.55 Mn |
| Dec 31, 2023 | 3.49 Mn |
| Sep 30, 2023 | 2.71 Mn |
| Jun 30, 2023 | 2.91 Mn |
| Mar 31, 2023 | 2.93 Mn |
| Dec 31, 2022 | 1.87 Mn |
| Sep 30, 2022 | 1.75 Mn |
| Jun 30, 2022 | 1.71 Mn |
| Mar 31, 2022 | 1.55 Mn |
| Dec 31, 2021 | 399,000.00 |
| Sep 30, 2021 | 1.21 Mn |